

Part 7: Steps taken for prequalification

I BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Lupin Limited submitted in 2018 an application for [HA715 trade name]¹ to be assessed with the aim of including [HA715 trade name] in the list of prequalified medicinal products for the treatment of HIV/AIDS.

[HA715 trade name] was assessed according to the ‘Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

September 2017	The manufacturer of one API was inspected for compliance with WHO requirements for GMP.
February 2018	The sites relevant for the bioequivalence study were inspected for compliance with WHO requirements for GLP and GCP.
July 2018	During the meeting of the assessment team the safety and efficacy data and the quality data were reviewed and further information was requested.
August 2018	The applicant’s response letter was received.
September 2018	During the meeting of the assessment team the additional efficacy data were reviewed and further information was requested.
September 2018	The manufacturer of the FPP was inspected for compliance with WHO requirements for GMP.
November 2018	The applicant’s response letters were received.
November 2018	During the meeting of the assessment team the additional quality data were reviewed and further information was requested. The safety and efficacy data were reviewed and found to comply with the relevant WHO requirements.
April 2019	The applicant’s response letter was received.
May 2019	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
June 2019	The applicant’s response letter was received.
August 2019	A desk review for evaluation of compliance of the manufacturer of one API for GMP was conducted and it met WHO requirements.
December 2019	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
January 2020	The applicant’s response letter was received.
January 2020	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
January 2020	The applicant’s response letter was received.
January 2020	The quality data were reviewed and found to comply with the relevant WHO requirements
January 2020	Product dossier accepted (quality assurance)
05 February 2020	[HA715 trade name] was included in the list of prequalified medicinal products.

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s responsibility.

II GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer, Commitments and Inspection status

Manufacturer of the finished product and responsible for batch release:

Lupin Limited
Plot No. 6A1, 6A2, Sector-17
Special Economic Zone
MIHAN
Nagpur
Maharashtra
441 108
India

Inspection status

The sites inspected were found to be in compliance with WHO requirements for GMP, GLP and GCP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

<https://extranet.who.int/prequal/>